Bayer
100 Bayer Boulevard
Whippany
New Jersey
07981
United States
726 articles with Bayer
-
Kojin launched with a $60 million Series A to focus on oncology and cell state biology led by Polaris Partners, Newpath Partners and Cathay Health.
-
Bayer is taking multiple shots at Parkinson’s disease with BlueRock dosing its first patient in a Phase I stem cell study, and AskBio is assessing a gene therapy treatment for the disease.
-
Bayer, like many biopharma companies, is presenting study results at the 2021 American Society of Clinical Oncology (ASCO) Annual meeting being held online June 4-8, 2021.
-
Bayer will nab exclusive rights to a differentiated alpha radionuclide, actinium-225 investigational compound, and a small molecule targeting prostate-specific membrane antigen.
-
Bayer Acquires Noria and PSMA Therapeutics to Expand Pipeline in Prostate Cancer
6/3/2021
Bayer today announced that it has entered into an agreement to acquire Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc.
-
Several biotech executives provided their thoughts on lessons learned from the pandemic and what they hope or expect to see moving forward in the industry.
-
Bayer Joins Greentown Labs' Corporate Partner Network
5/26/2021
Greentown Labs , the largest climatetech startup incubator in North America , today announced Bayer as the newest member of its growing corporate partner network.
-
Companies continue to report promising data for vaccines and therapies against COVID-19. Here’s a look.
-
Long-term Data on Vitrakvi® (larotrectinib) Further Demonstrate Strong Clinical Profile in Patients with TRK Fusion Cancer Regardless of Tumor Type and Age
5/19/2021
Bayer to present new data across four distinct analyses showcasing the consistent, long-term clinical profile for Vitrakvi® across TRK fusion cancer patients of all ages and multiple tumor types.
-
Celmatix’s drug program works by mimicking anti-Mullerian hormone, which acts as the molecular break that keeps women from depleting their ovarian reserves too quickly.
-
Bayer Announces New Commercial Leaders for Crop Science Division to Accelerate Growth and Drive Business Transformation
5/18/2021
Bayer today announced that Brett Begemann, Chief Operating Officer, Crop Science, will retire from his role after 38 years with the company.
-
Bayer Presents Latest Data and New Research to Advance Cancer Care within Oncology Portfolio at 2021 ASCO Annual Meeting
5/11/2021
Updated long-term efficacy and safety data of Vitrakvi® (larotrectinib) for patients with TRK fusion cancer from an integrated dataset, sub-analyses for TRK fusion cancer patients with primary central nervous system (CNS) tumors and lung cancer, respectively, as well as updated results from an intra-patient comparison to be featured
-
Bayer’s Finerenone Meets Primary Endpoint in Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes
5/10/2021
Finerenone significantly reduced the risk of the composite primary endpoint of cardiovascular death and non-fatal cardiovascular events versus placebo when added to standard of care
-
ESSA Pharma Announces Clinical Collaboration Agreement with Bayer to Evaluate the Combination of EPI-7386 and Darolutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
4/28/2021
ESSA Pharma Inc. (Nasdaq: EPIX) a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company has entered into a clinical trial collaboration and supply agreement with Bayer
-
Texas is quickly becoming a hotbed of biopharmaceutical activities, with Houston being one of the two top cities in the state that is leading the way.
-
Executives at pharmaceutical companies are known for receiving large salaries. When bonuses and stock options are factored into the picture, their annual compensation can jump into the range of tens of millions of dollars, like Pfizer’s Albert Bourla, Alex Gorsky from Johnson & Johnson, and Astra...
-
Bayer Pharmaceuticals Taps Two Leaders for New Roles in the U.S.
4/20/2021
Today, Bayer announced that two of its top Pharmaceutical executives will take on new leadership roles within the division to advance its position in key therapeutic areas.
-
Clinical Catch-Up: April 12-16
4/19/2021
It was a particularly busy week for clinical trial news, in part because of several big medical conferences. Here’s a look. -
Investigational Combination of Aliqopa® (copanlisib) and rituximab Significantly Increases Progression-Free Survival in Patients with Relapsed Indolent non-Hodgkin's Lymphoma
4/10/2021
Results from the randomized, double-blind, placebo-controlled Phase III trial CHRONOS-3 show a significant improvement in progression-free survival with the investigational combination of Aliqopa® and rituximab given intravenously in patients with relapsed indolent non-Hodgkin’s Lymphoma compared to the combination of rituximab and placebo.
-
New RestoraFIBRE® Daily Gummies offers convenient source of fibre
4/7/2021
RestoraFIBRE Daily Gummies contains inulin, a prebiotic fibre which helps support a healthy digestive system and promote regularity